180 related articles for article (PubMed ID: 33934271)
1. Comparative genomic characterization of melanoma of known and unknown primary.
Rassy E; Boussios S; Chebly A; Farra C; Kattan J; Pavlidis N
Clin Transl Oncol; 2021 Nov; 23(11):2302-2308. PubMed ID: 33934271
[TBL] [Abstract][Full Text] [Related]
2. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
[TBL] [Abstract][Full Text] [Related]
3. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari AN; Chatila WK; Arora A; Sanchez-Vega F; Kantheti HS; Rojas Zamalloa JA; Krieger P; Callahan MK; Betof Warner A; Postow MA; Momtaz P; Nair S; Ariyan CE; Barker CA; Brady MS; Coit DG; Rosen N; Chapman PB; Busam KJ; Solit DB; Panageas KS; Wolchok JD; Schultz N
Clin Cancer Res; 2021 Apr; 27(8):2226-2235. PubMed ID: 33509808
[TBL] [Abstract][Full Text] [Related]
6. Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis.
Ludwig SV; F Cheng P; Mangana J; Braun R; Dummer R; Koelblinger P
Eur J Dermatol; 2020 Dec; 30(6):699-709. PubMed ID: 33459260
[TBL] [Abstract][Full Text] [Related]
7. Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.
De Andrade JP; Wong P; O'Leary MP; Parekh V; Amini A; Schoellhammer HF; Margolin KA; Afkhami M; Melstrom LG
Ann Surg Oncol; 2020 Dec; 27(13):5240-5247. PubMed ID: 32909128
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.
Verver D; Grünhagen DJ; van Akkooi ACJ; Aarts MJB; van den Berkmortel FWPJ; van den Eertwegh AJM; de Groot JWB; Boers-Sonderen MJ; Haanen JBAG; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Tije AJT; Vreugdenhil G; Verhoef C; van der Veldt AAM
Cancer Immunol Immunother; 2021 Nov; 70(11):3123-3135. PubMed ID: 33774697
[TBL] [Abstract][Full Text] [Related]
9. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
[TBL] [Abstract][Full Text] [Related]
10. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
[TBL] [Abstract][Full Text] [Related]
11. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA; Lee SJ; Tan AC; El Naqa IM; Stephen Hodi F; Butterfield LH; LaFramboise WA; Storkus WJ; Karunamurthy AD; Conejo-Garcia JR; Hwu P; Streicher H; Sondak VK; Kirkwood JM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074904
[TBL] [Abstract][Full Text] [Related]
12. Molecular and genetic diversity in the metastatic process of melanoma.
Harbst K; Lauss M; Cirenajwis H; Winter C; Howlin J; Törngren T; Kvist A; Nodin B; Olsson E; Häkkinen J; Jirström K; Staaf J; Lundgren L; Olsson H; Ingvar C; Gruvberger-Saal SK; Saal LH; Jönsson G
J Pathol; 2014 May; 233(1):39-50. PubMed ID: 24399611
[TBL] [Abstract][Full Text] [Related]
13. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
14. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
15. Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Egberts F; Krüger S; Behrens HM; Bergner I; Papaspyrou G; Werner JA; Alkatout I; Haag J; Hauschild A; Röcken C
Melanoma Res; 2014 Apr; 24(2):131-6. PubMed ID: 24463461
[TBL] [Abstract][Full Text] [Related]
16. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations.
Montagnani V; Benelli M; Apollo A; Pescucci C; Licastro D; Urso C; Gerlini G; Borgognoni L; Luzzatto L; Stecca B
Oncotarget; 2016 May; 7(21):30365-78. PubMed ID: 27095580
[TBL] [Abstract][Full Text] [Related]
17. Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma.
Dutton-Regester K; Kakavand H; Aoude LG; Stark MS; Gartside MG; Johansson P; O'Connor L; Lanagan C; Tembe V; Pupo GM; Haydu LE; Schmidt CW; Mann GJ; Thompson JF; Scolyer RA; Hayward NK
Pigment Cell Melanoma Res; 2013 Nov; 26(6):852-60. PubMed ID: 23890154
[TBL] [Abstract][Full Text] [Related]
18. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.
Utter K; Goldman C; Weiss SA; Shapiro RL; Berman RS; Wilson MA; Pavlick AC; Osman I
Oncology; 2017; 93(4):249-258. PubMed ID: 28746931
[TBL] [Abstract][Full Text] [Related]
19. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
20. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]